Skip to main content
Log in

Preparation of Indapamide slow-release pellets

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

During the process of developing a slow-release formulation of indapamide, researchers created a drug-containing pellet coated with Eudragit® RS100 (Rohm GMbH & Co. KG, Darmstadt, Germany) to control the rate at which the drug was released. The two main variables were the agglomerants used in the pellet preparation and the amount of Eudragit RS100 used to coat them. The optimal outcome was indicated by the greatest number of drug-containing pellets recovered through an 18-to 24-mesh sieve and a satisfactory 24-hour release curve. The kinetics of dissolution fit the Higuchi kinetics model. Stability tests of the drug pellets showed no notable changes in the rate of drug release, related substances (mean byproducts or impurities from interactions or decompositions), and drug content.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Asmar R, Guez D, Malbezin M, Brault Y, et al. Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study.Arch Mal Coeur Vaiss. 1995; 88:1083–1087.

    PubMed  CAS  Google Scholar 

  2. Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group.J Hypertens. 1998;16:1677–1684.

    Article  PubMed  CAS  Google Scholar 

  3. Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension.Drugs. 2000;59:27–40.

    Article  PubMed  CAS  Google Scholar 

  4. Sancin P, Caputo O, Cavallari C, et al. Effects of ultrasound-assisted compaction on ketoprofen/ Eudragit RS100 mixtures.Euro J Pharm Sci. 1999;7:207–213.

    Article  CAS  Google Scholar 

  5. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.Eur J Pharm Sci. 2002;16:53–61.

    Article  PubMed  CAS  Google Scholar 

  6. Süslü I, Altinöz S. Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms.J Pharm Biomed Anal. 2002;30:357–364.

    Article  PubMed  Google Scholar 

  7. Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using a factorial design.Int J Pharm. 1997;154:49–57.

    Article  CAS  Google Scholar 

  8. Kachrimanis K, Ktistis G, Malamataris S. Crystallisation conditions and physicomechanical properties of ibuprofen-Eudragit® RS100 spherical crystal agglomerates prepared by the solventchange technique.Int J Pharm. 1998;173:61–74.

    Article  CAS  Google Scholar 

  9. Ketan A, Mehta MS, Kislalioglu W, et al. Release performance of a poorly soluble drug from a novel, Eudragit®-based multi-unit erosion matrix.Int J Pharm. 2001;213:7–12.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jia, W., Qiu, M., Sun, X. et al. Preparation of Indapamide slow-release pellets. Adv Therapy 21, 238–246 (2004). https://doi.org/10.1007/BF02850156

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850156

Keywords

Navigation